You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Angelini Pharma acquires CNS specialist Arvelle Therapeutics

Angelini Pharma has acquired Swiss biopharmaceutical company Arvelle Therapeutics for a total consideration of up to $960m.